Effect of branched-chain amino acids (BCAA) supplementation for patients with non alcoholic fatty liver disease (NAFLD)

Effect of branched-chain amino acids (BCAA) supplementation for patients with non alcoholic fatty liver disease (NAFLD) - Effect of BCAA for NAFLD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004972

Enrollment

Registered

2011-02-01

Start date

2010-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nonalcoholic fatty liver disease

Interventions

Branched-chain amino acids (BCAA)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patient with fatty liver. 2. Patient with insulin resistance (HOMA-R>=2) or hyperglycemia [fasting blood glucose >=126mg/dl or (blood glucose at 2 hr)>=200mg/dl in oral glucose tolerance test]. 3. Patient with abnormal ALT and/or ganma-GTP.

Exclusion criteria

Exclusion criteria: 1. Patient with viral hepatitis. 2. Alcohol consumer [alcohol intake (ethanol)>=20g/day]. 3. Patient with Hepatocellular carcinoma. 4. Diabetes patients treated with insulin or oral antihyperglycemic drug or uncontrolled patients (HbA1c>=8). 5. Patients who have already been taking BCAA. 6. Subjects who have already been taking amino-acid supplement. 7. Patients with amino-acid metabolism abnormality. 8. Subjects who are judged for non-approved by principal investigator.

Design outcomes

Primary

Measure	Time frame
To evaluate the liver function and insulin resistance at 12 weeks	—

Countries

Japan

Contacts

Public ContactHirofumi Uto

Kagoshima University Hospital Center for Gastroenterology

hirouto@m2.kufm.kagoshima-u.ac.jp099-275-5326

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026